This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ6D0TL_L.jpg
The antitrust agency sent the requests separately to both the companies, a regulatory filing said.
Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs.
The recent scrutiny by the antitrust agency to block Amgen (NASDAQ:AMGN)’s $27.8 billion deal to buy Horizon Therapeutics (NASDAQ:HZNP) has made investors jittery around the Pfizer-Seagen deal as well.
Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing.
